Back to News
Market Impact: 0.35
Genentech's Lunsumio-based Regimen Meets Primary Goal In Phase III Study In Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Genentech, a Roche affiliate, said its Lunsumio-based regimen significantly improved progression-free survival for follicular lymphoma patients in the Phase III CELESTIMO study. The positive late-stage trial result supports the regimen's clinical profile and could be a favorable catalyst for Roche's oncology portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- UBS downgrades Roche stock rating to neutral on valuation concerns
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist